Targeting ErbB3: The New RTK(id) on the Prostate Cancer Block

Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry - United Arab Emirates
doi 10.2174/187152211795495643
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Bentham Science Publishers Ltd.

Related search

New Strategies in Metastatic Prostate Cancer: Targeting the Androgen Receptor Signaling Pathway

Clinical Cancer Research
Cancer ResearchOncology
2011English

Targeting of erbB3 Receptor to Overcome Resistance in Cancer Treatment

Molecular Cancer
Cancer ResearchOncologyMolecular Medicine
2014English

The Promise of Anti-ErbB3 Monoclonals as New Cancer Therapeutics

Oncotarget
Oncology
2012English

PGC1α Drives a Metabolic Block on Prostate Cancer Progression

Nature Cell Biology
Cell Biology
2016English

Targeting Androgen-Independent Pathways: New Chances for Patients With Prostate Cancer?

Critical Reviews in Oncology/Hematology
GerontologyGeriatricsHematologyOncology
2017English

Targeting Invadopodia to Block Breast Cancer Metastasis

Oncotarget
Oncology
2011English

Driving Cancer Through ErbB3

Science-Business eXchange
2013English

Targeting TCTP as a New Therapeutic Strategy in Castration-Resistant Prostate Cancer

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2012English

Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer

Clinical Cancer Research
Cancer ResearchOncology
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy